Home/Pipeline/Ocular Tracer Program

Ocular Tracer Program

Amyotrophic Lateral Sclerosis (ALS)

Phase 1/2Active

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 1/2

Status

Active

Company

Amydis Diagnostics

About Amydis Diagnostics

Amydis Diagnostics is developing a first-in-class, non-invasive diagnostic platform that uses proprietary ocular tracers to detect molecular biomarkers in the eye via routine eye exams. This technology targets major unmet needs in neurodegenerative (e.g., Alzheimer's, Parkinson's, ALS), ophthalmic, and cardiovascular diseases by enabling earlier and more accessible diagnosis. The company is advancing its pipeline through human clinical trials with support from significant NIH grants and foundation awards, positioning itself to leverage the existing, widespread infrastructure of eye care providers as a new front line for systemic disease detection.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Ophthalmology Cardiology

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active